Format

Send to

Choose Destination
BMC Infect Dis. 2013 May 21;13:230. doi: 10.1186/1471-2334-13-230.

Soluble CD163 does not predict first-time myocardial infarction in patients infected with human immunodeficiency virus: a nested case-control study.

Author information

1
Department of Infectious Diseases, Copenhagen University Hospital, Kettegaard Allé 30, Hvidovre 2650, Denmark. andreas.knudsen@hvh.regionh.dk

Abstract

BACKGROUND:

Soluble CD163 (sCD163) has been associated with arterial inflammation and non-calcified plaques in human immunodeficiency virus (HIV)-infected individuals and has therefore been suggested as a predictive biomarker of myocardial infarction (MI).

METHODS:

We conducted a nested case-control study of 55 cases with first-time MI and 182 controls matched for age, duration of antiretroviral therapy (ART), gender, smoking, and no known cardiovascular disease. All patients had four available plasma samples, 1: Before initiation of antiretroviral therapy (ART), 2: Three months after ART, 3: One year before the case's MI, and 4: The last sample available before the case's MI. We used conditional logistic regression to estimate the association of sCD163 with first-time MI.

RESULTS:

The two groups had similar HIV-parameters and cardiovascular risk factors were equally distributed. There was no significant association between sCD163 and MI neither in samples obtained one year before (OR 1.05, CI 95% 0.85 - 1.29, p = 0.66) nor two months before (OR 1.20, CI 95% 0.98-1.47 p = 0.08).

CONCLUSION:

sCD163 did not prove to be a useful biomarker for prediction of first-time MI in a HIV-infected population.

PMID:
23692821
PMCID:
PMC3663777
DOI:
10.1186/1471-2334-13-230
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center